Liquidia Corporation (LQDA) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Liquidia Corporation.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.124 Chief Medical Officer, Dr. Rajiv Sagar, Chief Operating Officer and CFO, 00:00:05.124 -- 00:00:10.338 Michael Cassetta, Chief Commercial Officer, Scott Mumaw, and General Counsel, Rusty 00:00:10.338 -- 00:00:15.287 Schoenler. Before we begin, please note that today's conference call will contain forward-looking 00:00:15.287 -- 00:00:20.214 statements, including those statements regarding future results, unaudited and forward-looking 00:00:20.214 -- 00:00:25.061 financial information, as well as the company's future performance and or achievement. 00:00:25.061 -- 00:00:29.088 These statements are subject to known and unknown risks and uncertainties, which may 00:00:29.088 -- 00:00:33.935 cause our actual results or performance to be materially different from any future results 00:00:33.935 -- 00:00:37.160 or performance expressed or implied on this call. 00:00:37.160 -- 00:00:41.303 For additional information, including a detailed discussion of our risk factors, please 00:00:41.303 -- 00:00:45.529 refer to the company's documents filed with the Securities and Exchange Commission, which 00:00:45.529 -- 00:00:48.252 can be accessed on our website. 00:00:48.252 -- 00:00:52.137 I would now like to turn the call over to Roger for our prepared remarks, after which 00:00:52.137 -- 00:00:54.701 he will open the call for your questions. 00:00:54.701 -- 00:00:57.204 Good morning, everyone, and thank you for joining us today. 00:00:57.204 -- 00:01:02.070 In a little more than two weeks, May 24th to be precise, we will have reached the PDUFA 00:01:02.070 -- 00:01:06.670 goal date for Liquidia's first internally developed commercial product, Utrepia. 00:01:06.670 -- 00:01:11.154 an investigational inhaled dry powder formulation of tropostinil fo...